Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in NF1 Mutated GIST
NCT03109301Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selumetinib in gastrointestinal stromal tumor (GIST), sponsored by National Cancer Institute. Planned start Apr 2017; status: withdrawn.
02
Drugs
selumetinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03109301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109301.